TSE:APS Aptose Biosciences (APS) Stock Price, News & Analysis C$2.33 +0.13 (+5.91%) As of 06/9/2026 03:56 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsBuy This Stock About Aptose Biosciences Stock (TSE:APS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aptose Biosciences alerts:Sign Up Key Stats Today's RangeC$2.19▼C$2.3350-Day RangeC$2.00▼C$2.4052-Week RangeC$1.02▼C$2.59Volume5,800 shsAverage Volume3,913 shsMarket CapitalizationC$5.95 millionP/E RatioN/ADividend Yield0.39%Price TargetN/AConsensus RatingHold Company Overview Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada. Read More Aptose Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreAPS MarketRank™: Aptose Biosciences scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingAptose Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAptose Biosciences has received no research coverage in the past 90 days.Read more about Aptose Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptose Biosciences is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptose Biosciences is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for APS. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldAptose Biosciences has a dividend yield of 0.39%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthAptose Biosciences does not have a long track record of dividend growth.Read more about Aptose Biosciences' dividend. News and Social Media1.7 / 5News SentimentN/A News SentimentAptose Biosciences has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aptose Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders17.11% of the stock of Aptose Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions0.02% of the stock of Aptose Biosciences is held by institutions.Read more about Aptose Biosciences' insider trading history. Receive APS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APS Stock News HeadlinesAptose Biosciences (TSE:APS) Shares Cross Above 50 Day Moving Average - Time to Sell?June 3, 2026 | americanbankingnews.comAptose Biosciences, Inc.: Aptose Reports First Quarter 2026 ResultsMay 14, 2026 | finanznachrichten.deSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. But at a $1.75 trillion valuation and 266 times earnings, early institutional holders may be looking for someone to sell to. Dylan Jovine has identified a small company in Musk's supply chain that builds the power infrastructure behind Colossus - still trading at a fraction of its potential value. No IPO allocation required.June 10 at 1:00 AM | Behind the Markets (Ad)Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and ...March 31, 2026 | uk.finance.yahoo.comAptose Biosciences, Inc.: Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SECDecember 20, 2025 | finanznachrichten.deAptose reschedules special meeting on Hanmi acquisition planDecember 20, 2025 | msn.comAptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AMLOctober 16, 2025 | finance.yahoo.comAptose Biosciences Inc. (APS.TO) - Yahoo FinanceJuly 3, 2025 | ca.finance.yahoo.comSee More Headlines APS Stock Analysis - Frequently Asked Questions How have APS shares performed this year? Aptose Biosciences' stock was trading at C$2.12 at the beginning of 2026. Since then, APS stock has increased by 9.9% and is now trading at C$2.33. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (TSE:APS) issued its quarterly earnings data on Wednesday, May, 13th. The biotechnology company reported ($4.16) earnings per share (EPS) for the quarter. When did Aptose Biosciences' stock split? Aptose Biosciences's stock reverse split on the morning of Wednesday, February 26th 2025.The 1-30 reverse split was announced on Wednesday, February 26th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 26th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Aptose Biosciences? Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), VistaGen Therapeutics (VTGN), BlackBerry (BB) and Micron Technology (MU). Company Calendar Last Earnings5/13/2026Today6/10/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:APS CIKN/A Webaptose.com Phone+1-647-4799828FaxN/AEmployees31Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($10.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$154.69 million Net MarginsN/A Pretax MarginN/A Return on Equity115.24% Return on Assets-136.29% Debt Debt-to-Equity Ratio-98.74 Current Ratio0.55 Quick Ratio5.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$1.46 per share Price / Cash Flow1.60 Book ValueC($13.59) per share Price / Book-0.17Miscellaneous Outstanding Shares2,552,000Free FloatN/AMarket CapC$5.95 million OptionableNot Optionable Beta-1.38 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (TSE:APS) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
